Drug Profile
Research programme: vaccines - Akshaya Bio
Latest Information Update: 09 Mar 2023
Price :
$50
*
At a glance
- Originator Akshaya Bio
- Developer Akshaya Bio; Nuron Biotech
- Class Cancer vaccines; COVID-19 vaccines; Hepatitis B vaccines; Hepatitis C vaccines; Influenza virus vaccines; Malaria vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Hepatitis B; Hepatitis C; HIV infections
Highest Development Phases
- Discontinued Alphavirus infections; Cancer; COVID 2019 infections; Hepatitis B; Hepatitis C; HIV infections; Influenza virus infections; Malaria
Most Recent Events
- 03 Mar 2023 Discontinued - Preclinical for Hepatitis B in Canada (Parenteral)
- 03 Mar 2023 Discontinued for Cancer in Canada (Parenteral)
- 03 Mar 2023 Discontinued for COVID-2019 infections (Prevention) in Canada (unspecified route)